Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > GUD and INFLATION

<< Previous

Bullboard Posts

Next >>

Comment by Snowballgrowthon Apr 23, 2022 9:41am

82 Views

Post# 34626016

RE:RE:GUD and INFLATION

MrMugsy wrote:

Stockoman1 wrote: With a stagnant stock price, and paying no dividend, inflation has eroded the value of Gud stock held in your investment account.........just sayin...

It is true.
And the same could have been said about Paladin Labs throughout their early years.

What your initial investment in Paladin gave you was a CAGR of 27% over 19 years of patient business development. Addiitional money invested in later years would have returned much higher CAGR.

It's also important to understand that Knight may not be acquired in the same manner that Paladin was acquired - but - the final growth over 19 years at Knight should be much more impressive.

Knight's free cash generation and geographic reach is expected to outpace anything Paladin had. Each additional ROW drug that comes to market will have a revenue multiplier effect and any new geographies will also add to the effect.

Looking forward to seeing how EXELON adds to this in the early days of testing our ROW capabilities.

But to your point - have to really understand what you're buying here and if this is what you want to participate in.

Know your limits - play within them !!!!! : )